Bristol-Myers Squibb Company NYSE:BMY Price, Chart, News & Insight

Bristol Myers Squibb Reports Strong Phase 3 Results for ZENBEXUS in Relapsed Multiple Myeloma

Bristol Myers Squibb reported positive Phase 3 results for ZENBEXUS, or iberdomide, in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.

In the EXCALIBER-RRMM study, the combination reduced the risk of disease progression or death by 51% compared with daratumumab, bortezomib and dexamethasone. Median progression-free survival reached 42 months with ZENBEXUS versus 20 months for the control regimen, with a hazard ratio of 0.49 and a highly statistically significant result.

The trial enrolled 800 patients who had received one or two prior lines of therapy. The progression-free survival result builds on previously reported improvements in minimal residual disease-negative complete response, which supported the drug’s U.S. accelerated approval.

Bristol Myers said the safety profile remained consistent with previously reported findings. ZENBEXUS is an oral CELMoD therapy and is being positioned as a potential treatment option that can be used across a broader range of care settings, including community practices.

The new data are important because they provide stronger confirmatory evidence of clinical benefit beyond response depth alone. A near-doubling of median progression-free survival materially strengthens the treatment’s efficacy profile and could support broader physician adoption if the benefit remains durable in longer follow-up.

💬

European Investor 10-08-26

Bristol Myers Squibb Stock Falls 2.8% After Leerink Downgrade

Bristol Myers Squibb shares fell 2.8% to $59.41 after Leerink Partners downgraded the stock to Market Perform from Outperform.

Analyst David Risinger also cut the price target to $59 from $73, bringing the new target close to the stock’s current trading level and signaling a more cautious view on near-term upside potential.

The downgrade may reflect broader concerns around Bristol Myers Squibb’s growth outlook, including pressure from upcoming patent expirations on major products, the pace at which newer medicines can offset declining legacy revenue, and uncertainty around pipeline execution.

Investors are also closely watching the company’s ability to generate sufficient growth from newer oncology, cardiovascular and immunology products while managing increased competition across several key therapeutic areas.

The combination of a lower rating and sharply reduced price target appears to be weighing on the stock Monday, as the new target suggests limited expected appreciation from current levels.

💬

WS Investor 10-05-26

Bristol Myers Squibb’s ZENBEXUS Doubles MRD-Negative Complete Response Rate in Phase 3 Myeloma Trial

Bristol Myers Squibb (NYSE: BMY) reported positive Phase 3 EXCALIBER-RRMM results for ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.

At a median follow-up of 15.7 months, the ZENBEXUS-based regimen achieved an MRD-negative complete response rate of 41.1%, compared with 20.7% for daratumumab, bortezomib and dexamethasone. Overall response rates were also higher at 88.9% versus 76.1%, while complete response or better reached 45.9% versus 24.9%.

The benefit was consistent across prespecified subgroups, including patients previously treated with lenalidomide and those whose disease was refractory to lenalidomide. However, the regimen was associated with substantially higher Grade 3/4 neutropenia, at 84.3% versus 11.3%, and more Grade 3/4 infections, although peripheral sensory neuropathy was notably lower than with the comparator regimen.

ZENBEXUS in combination with daratumumab and dexamethasone received accelerated FDA approval in August for adults with multiple myeloma who had received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The progression-free survival portion of the Phase 3 trial remains ongoing.

💬

Global Finance News 09-25-26

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company.

The dividend is payable on November 2, 2026, to stockholders of record at the close of business on October 2, 2026.

💬

WS Investor 09-16-26

Bristol Myers Squibb’s Arlo-Cel Meets Primary Endpoint in Phase 2 Multiple Myeloma Trial

Bristol Myers Squibb (NYSE: BMY) announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial evaluating arlocabtagene autoleucel, or arlo-cel, in heavily pretreated patients with relapsed or refractory multiple myeloma.

The study met its primary endpoint, with arlo-cel demonstrating a statistically significant and clinically meaningful overall response rate in patients who had received at least four prior lines of therapy and were previously exposed to four major treatment classes, including BCMA-targeted therapy.

The trial also met key secondary endpoints, including complete response rate in patients treated with four or more prior lines, as well as overall and complete response rates among patients who had received at least three prior lines of therapy. Bristol Myers said arlo-cel’s safety profile was consistent with other CAR T-cell and GPRC5D-targeted therapies.

Arlo-cel is an investigational autologous CAR T-cell therapy targeting GPRC5D, a protein expressed on multiple myeloma cells independently of BCMA. This could provide an alternative treatment approach for patients whose disease has progressed following BCMA-directed therapies.

Bristol Myers plans to present detailed QUINTESSENTIAL results at an upcoming medical meeting. The company did not disclose specific response-rate percentages in the topline announcement.

💬

WS Investor 09-09-26

Bristol Myers Squibb Plans $2.3 Billion Houston Manufacturing Campus

Bristol Myers Squibb (NYSE: BMY) announced plans to invest approximately $2.3 billion in a new manufacturing campus in Houston, Texas, expanding the pharmaceutical company’s U.S. production capacity.

The roughly 600,000-square-foot facility will be located at Generation Park and is expected to create nearly 500 skilled jobs. The modular, multi-modal campus will be capable of manufacturing several types of medicines, including small molecules, biologics and antibody-drug conjugates.

The project represents another step in Bristol Myers Squibb’s broader commitment to invest $40 billion in the United States over five years across manufacturing, research and development, and technology.

Construction is also expected to support approximately 2,000 construction and indirect jobs between 2027 and 2030. BMS said the facility is being designed for long-term expansion and increased automation, allowing manufacturing capacity to evolve alongside the company’s drug pipeline.

For Bristol Myers Squibb, the Houston investment strengthens domestic manufacturing capacity and supply-chain resilience while providing additional infrastructure to support future medicine launches.

💬

The Investor 08-11-26

Bristol Myers Squibb Rises After Strong Q2 Results and Higher 2026 Outlook

Bristol Myers Squibb (NYSE: BMY) shares rose 1% on Thursday after the drugmaker reported strong second-quarter results and raised its full-year 2026 guidance, as investors welcomed continued momentum across the company's growth portfolio and improving earnings outlook.

Second-quarter revenue increased 6% year over year to $13.0 billion, while non-GAAP earnings per share rose 40% to $2.04. GAAP EPS climbed to $1.62 from $0.64 a year earlier, reflecting another quarter of solid earnings execution. The company also raised its full-year revenue outlook to approximately $49.0-$50.0 billion and increased its non-GAAP EPS guidance to a range of $6.75-$7.00.

Growth Portfolio Continues to Drive Performance

Bristol Myers' Growth Portfolio generated $7.6 billion in revenue, up 15% from a year ago, accounting for the majority of the company's sales. Growth was fueled by strong demand for newer therapies including Reblozyl, Camzyos, Breyanzi, Opdualag and Opdivo Qvantig.

Camzyos revenue surged 60%, Breyanzi climbed 41%, while Reblozyl increased 29%, highlighting the company's successful transition toward newer, high-growth medicines.

Meanwhile, the Legacy Portfolio declined 4%, as continued growth in Eliquis was more than offset by expected generic competition for products such as Revlimid and Pomalyst.

Pipeline Progress Supports Long-Term Outlook

Management highlighted continued progress across its pipeline and emphasized that the growing contribution from newer products positions the company for sustainable long-term growth. The higher full-year guidance reflects confidence in continued commercial execution and the momentum of recently launched therapies.

What to Watch

The positive share reaction suggests investors are focusing on Bristol Myers' accelerating growth portfolio and improved earnings outlook despite ongoing patent headwinds for legacy products. Going forward, markets will closely monitor continued adoption of the company's newer therapies, upcoming clinical trial results and its ability to offset declining legacy drug sales with sustained growth from recently launched medicines.

💬

WS Investor 07-30-26

Bristol Myers Squibb Jumps 5% as Growth Portfolio Transition Gains Credibility

Bristol Myers Squibb shares are up 5% in trading on April 30, as a convincing Q1 2026 beat reassured investors that the company's transition away from legacy products is firmly on track.

Revenue came in at $11.49 billion, beating the $10.69 billion consensus by 7.4%, while adjusted EPS of $1.58 topped the $1.42 estimate by 11.1%. The driver was a clear and accelerating split between old and new: the Growth Portfolio, which now accounts for roughly 54% of total sales, delivered 12% revenue growth to $6.2 billion, led by Camzyos, Breyanzi and Reblozyl. International revenues rose 11%, contrasting with a 1% decline in US revenues, underscoring a shifting geographic mix as newer growth brands deliver double-digit gains worldwide. (Simply Wall St, IndexBox)

The legacy drag, while real, was anticipated. Legacy Portfolio revenues fell 6% to $5.3 billion as generic competition continued to erode older products, partly offset by a 16% rise in Eliquis worldwide sales to $4.1 billion. Non-GAAP EPS fell 12% year-on-year to $1.58, but management reaffirmed full-year guidance of $46 to $47.5 billion in revenue and $6.05 to $6.35 in non-GAAP EPS, noting that both metrics are trending toward the upper end of those ranges. (FinancialContent)

What is lifting the stock beyond the headline beat is the pipeline narrative. CEO Christopher Boerner pointed to multiple pivotal data readouts ahead, and the company has recently inked deals with Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics and Ajax Therapeutics, signaling aggressive expansion across oncology and beyond.

💬

WS Investor 04-30-26

Bristol Myers Squibb and Pfizer announced a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis (apixaban) directly to U.S. patients through the online platform, expanding access to the widely prescribed blood thinner.

Starting April 27, 2026, a 30-day supply of Eliquis will be available for $345, providing a lower-cost option for cash-paying patients and increasing pricing transparency. The move builds on earlier direct-to-patient initiatives aimed at improving affordability and access.

The companies said the partnership supports efforts to reduce barriers to essential medications, particularly for patients managing conditions such as atrial fibrillation and blood clots.
Business Wire

💬

The Investor 04-26-26

Bristol Myers Squibb announced the expansion of its “Standing in the Gaap” program to improve equitable care for patients with multiple myeloma, marking the initiative’s 10th anniversary.

As part of the expansion, the company is launching one of the largest U.S. surveys on multiple myeloma, engaging over 1,000 patients, caregivers, and healthcare providers to better understand persistent gaps in care. Developed with input from major patient advocacy groups, the survey aims to capture real-world experiences and identify barriers faced by underserved communities.

Originally launched in 2016 to address disparities affecting African American patients, the program has reached thousands through educational initiatives and built a large digital community. Bristol Myers Squibb said insights from the new survey will guide future programs, partnerships, and strategies to enhance access, education, and support across the multiple myeloma care ecosystem.
Business Wire

💬

European Investor 03-31-26

NYSE:BMYFollow

NYSE:BMY